32 results about "Post menopausal" patented technology

The invention relates to the technical field of data processing, and discloses a postmenopausal osteoporosis risk assessment system based on big data, a data preprocessing module is used for collecting multidimensional data of postmenopausal women and processing the collected data to obtain preprocessed data; the feature extraction module is used for extracting features related to the postmenopausal osteoporosis risk from the preprocessed data to obtain target feature data; the risk assessment module is used for constructing a risk assessment model based on the target feature data, inputting the original data of the to-be-assessed postmenopausal female into the risk assessment model after data preprocessing and feature extraction, and outputting a risk assessment result of osteoporosis of the to-be-assessed female; the result visualization module is used for visualizing the risk assessment result and providing corresponding intervention suggestions according to different risk levels; according to the invention, early prevention and intervention of postmenopausal osteoporosis can be realized.

The invention discloses application of pinoresinol diglucoside in increasing short-chain fatty acids in postmenopausal intestinal tracts and relieving postmenopausal intestinal inflammation, and belongs to the field of medicines. The pinoresinol diglucoside can regulate the abundance of bacteria such as Akecmann bacteria, other mycobacteria, parabacteroides and ruminococcus in intestinal tracts and promote the expression of short-chain fatty acids in the postmenopausal intestinal tracts, so that the postmenopausal intestinal inflammation and osteoporosis are relieved. The invention opens up a new clinical approach for treating diseases related to intestinal flora disorder of postmenopausal women.

The invention provides a construction method and equipment of a fracture risk prediction model, a medium and a program product, and relates to the field of intelligent medical treatment. The method comprises the following steps: acquiring basic data of a T2DM osteoporosis patient as a training set sample; the training set samples are divided into a fracture group and a fracture-free group; performing statistical analysis on the basic data, representing continuous variables conforming to normal distribution by using mean + / -standard deviation, and comparing the difference between the two groups through independent sample t inspection; adopting median and quartile to describe continuous variables which do not conform to normal distribution; through single-factor and multi-factor analysis, screening fracture influence characteristics of the osteoporosis patient from the basic data; and constructing a prediction model of the fracture risk of the osteoporosis patient based on the prediction variables. A special group of postmenopausal female diabetes is used as a research object, difference characteristics are analyzed, a prediction model is constructed, and early prevention and treatment of osteoporosis fracture patients are achieved.

Provided herein are methods of treating symptoms associated with menopause, perimenopause and / or post-menopause in a subject in need thereof by administering to the subject compositions comprising a triple reuptake inhibitor (e.g., Compound 1).

The invention discloses application of securinine in preparation of a medicine for relieving anxiety disorder of postmenopausal women. Female menopausal related mood disorder diseases are researched by constructing a bilateral ovariectomy mouse model, and mouse anxiety-like behaviors induced by ovariectomy can be quickly relieved within 30 minutes by single administration of a natural product securinine. The invention provides a medicine for treating postmenopausal female anxiety disorder, the medicine takes effect quickly, not only provides a brand new medicine candidate for quick intervention of menopausal related anxiety, but also defines a corresponding medication scheme, and has practical application potential.

The utility model relates to the technical field of medical auxiliary instruments, in particular to a novel uterine manipulator which is characterized by comprising a vertical rod and a sucker fixedly arranged at the top end of the vertical rod, the sucker and the vertical rod are coaxially arranged, and the sucker is used for being fixedly adsorbed to the atrophic cervix uteri and the front wall and the rear wall of the top vagina. The uterine manipulator can be used by a female patient with postmenopausal cervical atrophy, and can be fixedly adsorbed with the front wall and the rear wall of the atrophy cervix uteri and the front wall and the rear wall of the top end vagina through the suction cups, so that the atrophy cervix uteri and the top end of the vagina are fixed; gaps among the cervix uteri, the vagina, the bladder and the rectum can be fully expanded, and the risks that the operation difficulty is increased and the bladder, the ureter and the rectum are injured due to gap folding are avoided.

The application discloses application of pinoresinol diglucoside in increasing short-chain fatty acids in the postmenopausal intestinal tract and relieving postmenopausal intestinal inflammation, and belongs to the medical field. The pinoresinol diglucoside can regulate the abundance of Akkermansia, another branch bacteria, parabacteroides, rumenococcus and other genera in the intestinal tract, promote the expression of short-chain fatty acids in the postmenopausal intestinal tract, and then relieve postmenopausal intestinal inflammation and osteoporosis. The application opens up a new clinical approach for the treatment of postmenopausal women and diseases related to intestinal flora disorder.

The invention relates to the related technical field of medical drugs, in particular to an anti-osteoporosis pill based on hydroxyapatite combined Erzhi pill and a preparation method thereof, the pill comprises a nano-hydroxyapatite carrier (Ca / P = 1.67: 1, and the particle size is 20-100nm), Erzhi pill active components (the compatibility of ligustrum lucidum ait total glycoside and eclipta ethyl acetate part is 1: 1) and pharmaceutical auxiliary materials, through ionic bond / hydrogen bond loading, the drug loading ratio is (5-20): 1. The preparation method comprises the following steps: synthesizing nano-hydroxyapatite by a hydrothermal method, extracting active components of Erzhi pills by using ethanol, adsorbing and carrying medicines by using a buffer solution with the pH value of 7.4, and tabletting and forming. According to the anti-osteoporosis pill based on the hydroxyapatite combined Erzhi pill and the preparation method of the anti-osteoporosis pill, the synergistic anti-osteoporosis effect is achieved by up-regulating bone morphogenetic genes (osterix, OCN), inhibiting osteoclast genes (c-Src, cathepsin K) and regulating an LCN2 / Sema3A pathway, the targeting property is high, the bioavailability is high, and the anti-osteoporosis pill is suitable for treating postmenopausal and senile osteoporosis.

The invention discloses an application of loperamide in preparation of a medicine for treating osteoporosis, and belongs to the field of development of new application of medicines. Loperamide has the effects of inhibiting aging, increasing osteogenic differentiation of bone marrow mesenchymal stem cells and preventing osteoporosis of aged and postmenopausal mice; meanwhile, at the cellular level, loperamide can reduce expression of senescence factors in mouse mesenchymal stem cells, promote senescence cell apoptosis and inhibit cell senescence; and a new choice is provided for the treatment of senescence-related osteoporosis drugs.

The invention provides a method, equipment, medium and program product for predicting the osteoporosis risk of postmenopausal diabetes people, and relates to the field of intelligent medical treatment. The method comprises the following steps: acquiring one or more predictive factors of an age, a menopausal age, a diabetes disease course, PINP, CTX and an FF score of a subject; the subject is a postmenopausal diabetes patient; calculating a risk score based on the predictive factor, and outputting an auxiliary predictive result of the risk probability of osteoporosis of the subject according to the risk score; when the risk score is greater than a first threshold value, outputting an auxiliary prediction result that the probability of occurrence of osteoporosis risk of the subject is large; and when the risk score is smaller than a first threshold value, outputting an auxiliary prediction result with a small probability of occurrence of osteoporosis risk of the subject. The osteoporosis risk of postmenopausal diabetes people is predicted specifically aiming at the postmenopausal diabetes people.

This invention discloses the application of an inhibitor of transcription factor C / EBPβ in the preparation of a drug for treating postmenopausal osteoporosis. This invention also discloses the application of transcription factor C / EBPβ in screening drugs that reduce postmenopausal FSH levels, wherein the drugs inhibit the expression of transcription factor C / EBPβ. Furthermore, this invention discloses the application of compounds #11a and CF3CN in the preparation of a drug for treating postmenopausal osteoporosis. This invention reveals for the first time that the C / EBPβ-AEP pathway participates in promoting FSHβ synthesis in a menopausal model. By reducing the transcription factor activity of C / EBPβ, it can reduce FSH expression at the pituitary gland, promote osteogenic differentiation, inhibit osteoclast resorption, and effectively alleviate PMOP symptoms. Compounds #11a and CF3CN can effectively achieve both anti-bone resorption and bone formation-promoting functions, achieving coupled treatment of PMOP.

The invention relates to the field of medical preparations, in particular to application of ingenol in preparation of a medicine for treating liver injury of postmenopausal women. The ingenol intervenes in OVX to induce a postmenopausal obese mouse, and the ingenol is proved to be capable of remarkably reducing the weight and fat content of the mouse, reducing serum TC, TG and LDL-c level rise, improving hepatocyte swelling and reducing the number of liver fat droplets, and also capable of remarkably reducing serum AST and ALT level rise caused by OVX and relieving liver injury induced by OVX. Therefore, the ingenol can be used for effectively treating the liver injury of the postmenopausal women, and can be used for preparing a medicine for treating the liver injury of the postmenopausal women and a medicine for reducing the level of a liver injury marker in serum. The method can provide a new direction and strategy for future development and application of ingenol.

The invention relates to the field of medicine application of organic compounds, in particular to application of puerarin-6 ''-O-xyloside in preparation of medicine for treating postmenopausal lipid metabolism disorder. Animal experiments of postmenopausal lipid metabolism disorder mice induced by ovariectomy and high fat diet show that the puerarin-6 ''-O-xyloside significantly reduces the TG, TC and LDL-C levels of the mice, and also increases the HDL-C level; the liver function is improved, the ALT and AST levels are reduced, the balloon-like degeneration of liver cells and the accumulation of lipid droplets in the cells are reduced, and the volume of fat cells is reduced. From the aspect of mechanism, the PPARalpha pathway is activated to regulate and control gene expression related to fatty acid oxidation, so that liver beta-oxidation is promoted, and ectopic lipid deposition is inhibited. Therefore, the puerarin-6 ''-O-xyloside can be used for preparing a PPAR alpha agonist, a medicine for treating postmenopausal lipid metabolism disorder and a medicine for treating dyslipidemia.

The invention relates to the technical field of health risk assessment, in particular to a postmenopausal osteoporosis risk prediction and traditional Chinese and western medicine intervention management system. The system quantifies the trend risk of the bone mineral density through the deviation change of the bone mineral density risk value in time sequence, and combines the initial bone mineral density risk to divide the group and analyze and identify the risk degree of the group; coupling the drop fluctuation characteristics of hormones with the change of bone metabolism markers to obtain the comprehensive metabolic risk influence degree; determining the comprehensive influence degree of osteoporosis by utilizing the group comprehensive bone mineral density risk degree dynamic adjustment and combining the external risk influence degree and the comprehensive metabolic risk influence degree; and based on the osteoporosis comprehensive influence degree of the sample data, training a neural network model to carry out risk prediction. According to the method, the risk model is constructed by considering the multi-dimensional influence of hormone metabolism and behavioral habits of the postmenopausal patient and the multi-dimensional coupling evaluation value, so that the risk prediction accuracy is improved, and more comprehensive and reliable data support is provided for bone health management of postmenopausal women.

The utility model provides a hysterectomy positioning and lifting device which comprises a positioning rod, a hinged rotating rod is arranged at the end of the positioning rod, a sleeve connected with the positioning rod in a sleeved mode is arranged on the positioning rod, an arc-shaped supporting cup is arranged at one end of the sleeve, and hinged locking grips are arranged on the two sides of the other end of the sleeve. The diameter of the positioning and lifting device adapts to postmenopausal vulva and vaginal orifice, and the positioning and lifting device can smoothly pass through. The part between the cervix uteri and the vaginal arch can be accurately positioned at the postmenopausal atrophy cervix uteri, and the device is suitable for patients with cervix uteri of different sizes. The part needing to be separated or cut open can be clearly displayed under a laparoscope, and the operation difficulty is simplified.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to anastrozole-containing tablets, application and a preparation method thereof.The anastrozole-containing tablets are composed of anastrozole, salidroside, glyceryl monostearate, microcrystalline cellulose, xylitol, a disintegrating agent and a lubricant, according to the standard of Chinese Pharmacopoeia 2020 edition, the dissolution rate of the anastrozole-containing tablets in water within 10 min reaches 90% or above, and the dissolution rate of the anastrozole-containing tablets in water within 10 min reaches 90% or above; acceleration tests prove that the content of related substances is low, the tumor cell apoptosis index is remarkably increased in a postmenopausal breast cancer rat model, tumor cell proliferation is effectively inhibited, the synergistic anti-tumor effect is shown, and the pharmaceutical composition is suitable for further application and popularization.

This invention discloses a multi-functional traditional Chinese medicine composition, an oral preparation, its preparation method, and its applications. The traditional Chinese medicine composition comprises the following components in parts by weight: Epimedium 2-8 parts, dried ginger 2-8 parts, licorice 2-8 parts, ginseng 1-4 parts, Poria cocos 1-4 parts, and Salvia miltiorrhiza 1-4 parts. This traditional Chinese medicine composition has multiple effects, simultaneously preventing and treating impotence, myocardial infarction, estrogen deficiency (typical estrogen deficiency such as postmenopause) related diseases (including osteoporosis, obesity, and uterine atrophy), and anti-fatigue effects, with significant efficacy and a very high degree of applicability. Moreover, the composition is simple, with all components being medicinal and edible herbs, ensuring high safety. It can be extracted using conventional water decoction methods to produce extracts, which can then be formulated into various oral preparations, including drugs, health foods (functional foods), or other food products, possessing significant market value.

The present invention provides methods for the assessment of an adnexal mass predetermined to be benign or asymptomatic (e.g., asymptomatic or benign adnexal mass) in a variety of subjects (e.g., pre- and post-menopausal women). In particular, the present invention provides methods for determining the malignancy risk of ovarian tumors in selected subjects (e.g., benign or indeterminate risk).

The invention discloses the application of the Chinese wolfberry fruit-glossy privet fruit and calcitriol composition in the medicine for treating postmenopausal osteoporosis for the first time, and through three-layer research of'in vitro cell-animal model-molecular pathway ', it is clear that the composition can bidirectionally regulate and control kidney vitamin D metabolic enzyme by activating'PI3K-AKT' signal pathway for the first time, so that the curative effect on postmenopausal osteoporosis is achieved. Further, the serum 25 hydroxyl vitamin D and blood calcium level are improved, and the bone mineral density is improved. The mechanism provides a modern molecular biology support for the traditional Chinese medicine theory of'kidney dominating bone ', and also establishes a new path of'regulating kidney metabolic enzyme to treat osteoporosis'. By optimizing the metabolic bone protection effect of the vitamin D, bone loss of ovariectomized mice is effectively delayed, meanwhile, the vitamin D and calcitriol play a synergistic effect, and the vitamin D has a multi-target bone protection effect in postmenopausal PMOP, has anti-osteoporosis activity and can be used for treating the PMOP.

Provided is a composition for inhibiting bone density loss. Specifically, the present invention provides a composition for inhibiting bone density loss that contains rhamnose and is for administration to postmenopausal women. The inhibition of bone density loss in this embodiment can be the inhibition of the risk of bone density loss in healthy postmenopausal women. The composition of this embodiment can be a composition taken at a daily dose of 0.1-2 g. The composition can be administered daily for at least 12 weeks. The present invention also provides a method for imparting a bone density loss inhibitory effect to a composition by including rhamnose in the composition.

This invention belongs to the field of assisted reproductive technology, specifically relating to a controlled ovarian stimulation method and supporting drug composition for in vitro fertilization-embryo transfer. The core of this invention does not use GnRH agonists or antagonists throughout the entire process, employing clomiphene combined with individualized, adequate doses of postmenopausal gonadotropins to induce ovulation. A combined packaged drug composition of these two drugs is provided to suit the needs of individuals with high, normal, and low ovarian responses. This method achieves an early ovulation rate of less than 0.2%, an incidence of ovarian hyperstimulation syndrome of less than 1%, and reduces the cost of ovulation induction drugs per cycle by more than 80% compared to existing mainstream methods. It also boasts a stable clinical pregnancy rate and can be widely applied to assisted reproductive ovulation induction treatment for various infertile patients, significantly reducing their economic and time burden.

The invention relates to the technical field of traditional Chinese medicine compound compositions, in particular to a traditional Chinese medicine composition for treating kidney deficiency, blood stasis and phlegm type postmenopausal female coronary heart disease. According to the technical scheme, the preparation method comprises the following steps: taking the following raw materials in parts by mass: 20-30 parts of prepared rehmannia root, 10-20 parts of Chinese yam, 5-15 parts of dogwood, 5-15 parts of rhizoma alismatis, 10-20 parts of moutan bark, 10-20 parts of poria cocos, 3-9 parts of turmeric, 5-10 parts of curcuma zedoary and 10-20 parts of verbena. The preparation method comprises the following steps: putting the medicinal materials into a clean container, washing with clear water, putting into a marmite or a ceramic pot, adding 5 times by weight of water, boiling with big fire, decocting with small fire for 1-2 hours, and filtering out medicine residues with a filter screen or gauze after the decoction is finished, thereby obtaining the liquid medicine. Adding clear water with the same amount as that in the first time into medicine residues again, and decocting according to the method. And merging the liquid medicines obtained by decocting twice, adding ethanol with the volume concentration of 80% for treatment, standing, filtering and recycling, and concentrating at 60 DEG C until the relative density is 1.30-1.36 to obtain the extract. The pharmaceutical composition and a pharmaceutically acceptable carrier are prepared into medicines in dosage forms such as ointment, oral liquid, granules and the like.

The present disclosure relates to a composition comprising Lactobacillus rhamnosus, Lactobacillus reuteri and 2 '-fucosyllactose for use as a supplement to promote vaginal health in a menopausal or post-menopausal woman.

Compositions and methods for treating one or more symptoms associated with vaginal atrophy or discomfort are disclosed. The compositions include an effective amount of one or more of the active agents selected from pectin (P), hyaluronic acid (HA), and collagen (Cg), in a pharmaceutically acceptable carrier, for vaginal delivery. The disclosed compositions are useful in treating one or more symptoms associated with vaginal atrophy. Example subjects include postmenopausal women or premenopausal women who experience these symptoms as a result of breastfeeding, intensive vaginal douching, cigarette smoking, autoimmune conditions such as Sjogren's syndrome, pathologic conditions such as diabetes, premature ovarian insufficiency, bilateral oophorectomy, ovarian failure due to radiation or arterial embolization, hypothalamic-pituitary disorders. Additionally, the disclosed compositions are useful in generally alleviating vaginal discomfort such as pH imbalance, vaginal dryness, burning, itching, vaginal discomfort, pain and burning when urinating, dyspareunia (painful sex), and spotting during intercourse.

The present application relates to the technical field of health risk assessment, in particular to a postmenopausal osteoporosis risk prediction and traditional Chinese and western medicine intervention management system. The system quantifies the trend risk of bone mineral density by the deviation change of bone mineral density risk value in time sequence, combines with the initial detection of bone mineral density risk to divide groups and analyze and identify the group risk degree; the comprehensive metabolic risk influence degree is obtained by coupling the hormone drop fluctuation characteristics with the bone metabolism marker change; the osteoporosis comprehensive influence degree is determined by using the group comprehensive bone mineral density risk degree dynamic adjustment, combining with the external risk influence degree and the comprehensive metabolic risk influence degree; and the neural network model is trained based on the osteoporosis comprehensive influence degree of sample data to predict the risk. The present application considers the multidimensional influence of postmenopausal patient's internal hormone metabolism and behavior habit, constructs the risk model by multidimensional coupling evaluation value, improves the risk prediction accuracy, and provides more comprehensive and reliable data support for the bone health management of postmenopausal women.

The invention discloses an ultra-fine single-channel electronic hysteroscope with negative pressure function, which includes a barrel, a handle is sleeved on the rear end of the barrel, the barrel is a single-channel straight tube, the outer diameter of the barrel is not more than 4mm; the wall thickness of the barrel is not more than 0.13mm; an image acquisition end is fixedly arranged at the front end of the barrel, and the image acquisition end seals the front end of the barrel; the outer diameter of the image acquisition end is not greater than the outer diameter of the barrel; a through hole for the entry and exit of uterine distention fluid is arranged on the outer wall of the barrel, and a three-way joint is arranged at the rear end of the barrel, and the three-way joint includes a first interface, a second interface and a third interface; a control switch is arranged on the three-way joint. The hysteroscope of the invention is suitable for performing uterine cavity examination on elderly women after menopause in hospital outpatient clinics, and it is easy to operate and has the advantages of fast examination speed, and has both the function of uterine distention and the function of negative pressure suction, which fully meets the examination needs of hospital outpatient clinics.

The invention relates to a calcium-containing food supplement that differs from its counterparts in that it contains Lysine amino acid, which contributes to the absorption of calcium, and Arginine amino acids, which enable the utilisation of calcium in the metabolic process, which is generally developed for use in supporting bone and bone development metabolism, in order to support the prevention of Osteoporosis, Maleostasis, seen in women after menopause; in adult men, to contribute positively to the solution of problems in the absorption and utilisation of calcium that occur in bone metabolism with aging; To protect dental health and in dental implant treatment, to ensure the stability of the implant by surrounding the implant surface of the bone tissue; to ensure that children have stronger bones and, to the extent permitted by genetic factors, longer bones and therefore taller stature at the developmental age; Depending on various factors, to support the absorption and transport of calcium in skeletal problems, to support faster and better union of bone fractures.

The invention is suitable for the technical field of biological medicines and gynecological external preparations, and provides a temperature-sensitive gynecological gel for preventing vaginal mucosa atrophy and a preparation method thereof. The gynecological gel is prepared from the following raw materials in parts by weight: 70 to 95 parts of temperature-sensitive gel matrix, 1 to 5 parts of prebiotics, 0.01 to 0.1 part of superoxide dismutase, 1 to 3 parts of modified glycyrrhizic acid and 2 to 4 parts of sustained release microspheres of which the internal effective component is tanshinone IIA (at) collagen-sodium hyaluronate, the anti-inflammatory and anti-oxidation effects of the modified glycyrrhizic acid, the safe microcirculation improvement effect of the tanshinone IIA and the moisturizing, mucous membrane tissue repair promotion and anti-inflammatory effects of the collagen and the sodium hyaluronate have a synergistic effect, so that the vaginal atrophic mucous membrane is efficiently repaired; the invention also discloses a preparation method of the temperature-sensitive gel. The gel preparation is stable in preparation process and high in safety, is suitable for preventing and treating vaginal mucosa atrophy caused by postmenopausal or hormone level fluctuation, and has a good clinical application prospect.

The application discloses application of hsa-miR-144-5p as a postmenopausal osteoporosis diagnosis marker. The application adopts high-throughput gene chip technology to detect serum miRNA expression profiles of PMOP patients, and compares with postmenopausal non-osteoporosis population, screens differential expression miRNAs between the two, further verifies the differential level of the selected miRNA between the PMOP patients and n-PMOP through real-time fluorescent quantitative PCR technology, confirms the clinical application value of the screened marker, and finally provides a simple and easy, high-precision biomarker for clinical PMOP diagnosis.

The present disclosure is directed to generally methods and / or compositions for treating mammographic breast density and / or breast stiffness in a patient in need thereof, such as a pre-menopausal, a peri-menopausal or a post-menopausal patient, comprising the administration of an effective amount of androgenic agent and an effective amount of an aromatase inhibitor. The present disclosure is also directed to methods and / or compositions for reducing breast pain. The present disclosure is also directed to method and / or compositions for reducing elasticity and / or decreasing mechano-transduction on the genome of breast cells. The present disclosure is also directed to methods and / or compositions for stabilizing and / or increasing the levels of androgen receptor expression in breast tissue.